Back to News
Market Impact: 0.15
Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical Trial
Source: globenewswire.com
Healthcare & BiotechCompany Fundamentals
A milestone advanced Clearmind's clinical program for CMND-100, which the company is developing as a potential treatment for alcohol use disorder. The article provides no milestone details, clinical results, or numerical data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
CMND0.40
More News
- SK Hynix Posts Record Profit Amid AI Rush
- SK Hynix third-quarter profit sharply beats estimates on AI memory boost
- Anthropic's IPO could be 'speculative fiction' or a 'generational moment' — investors are split
- Anthropic Gives Traders a Pure-Play Bet on Frontier AI
- Analysis-Hold or sell? High Treasury yields spur US banks to rethink bond portfolios
- Labubu-maker Pop Mart's shares extend declines as third-quarter sales plunge